Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
PLAYin CHOC is an innovative, premium and award-winning manufacturer of vegan organic eco-friendly toys and chocolates. Its products are allergen-free, plastic-free, 100% organic and inspire creative play. Since its launch, PLAYin CHOC has sold approximately 50,000+ units in 21 countries. Additionally, potential stockists for its products are estimated at 100,000 in the UK and 1 million globally. Now, PLAYin CHOC is planning to take its product to the market via high-end food supermarkets; independent food, confectionary and gift shops; travel retail market; direct to the consumer via subscription; and international distributors. Funds raised will be used to increase growth by securing larger and permanent premises and intensify targeted marketing at trade & consumer shows and online.
days to go:
Expired
investment:
£278,450
Gendius' has created intellin, an application through which people can track diabetes and make a good decision to reduce the risk of diabetes. It is on a mission to make sure that every person with diabetes knows their risk of complications and how to control them. The company has been launched across the EU with over 3,500 downloads in the EU and UK. In 2018, the company won £25K Momentum award to complete UX/UI research and, it has passed ISO27001. Recently, it has been invited to HIMSSHealth2.0 conference for the application's live demo.
days to go:
Expired
investment:
£518,630
Marine Power Systems (MPS) states that it has developed a technology that can harness wind power, wave power or combined wind and wave energy at grid scale. It argues that governments worldwide are looking for alternative sources to meet global energy consumption needs. MPS endeavours to usher in an energy revolution and become a contender in the floating offshore energy market that is set to be worth over $100 billion by 2035. MPS claims to have successfully tested its medium-scaled prototype in the ocean, demonstrating the ease of transportation, deployment, and showcasing the devices ability to generate grid compliant electricity. The company has been awarded a £12.8 million grant by the European Union (EU) to deliver a full scale, grid-connected commercial demonstrator in 2022. It says it will use the investment to conduct its final phase of development and testing before taking its devices to market in Q1 of 2024.
days to go:
Expired
investment:
£4,151,001
Aguulp innovates and curates liquid formulas using liposomal technology. The company asserts that vitamins in pill form have an absorption rate as low as 5% which is further eaten by stomach acid upon consumption before a person gets a chance to absorb it. Agullp aims to resolve this. Its product, NutriProtect, shields nutrients from corrosive stomach acid and helps 98% of nutrients reach the small intestine for absorption. The company estimates that over 3 million people in the UK and more than 10 per cent of the world’s population is malnourished for a variety of reasons, including environmental pollution, unhealthy diets and stressful lifestyles that block nutrient absorption and compound deficiencies. Aguulp aims to change this with its product line that includes Aguulp for Gut, Aguulp for Brain, and Aguulp for Immunity. The company will use 55.6% of the investment for marketing purposes, 44.2% for paying their staff, and 0.2% as other expenses.
days to go:
Expired
investment:
£317,993
QFinds is a purpose-built hiring tool that enables employers to easily and efficiently pre-screen candidates, conduct interviews and generate employment contracts. The company asserts that it is a UK government vetted 'Kickstart Scheme' representative and can get small businesses grants to hire interns having already processed over 100 job applications. QFinds claims that its app has been downloaded 2 million+ times garnering 24,000 reviews averaging 4.8/5 stars. QFinds also points out that bad hirings cost the UK up to £6.7 billion in turnover, productivity, and training. It seeks to change this and disrupt the £39 billion recruitment market. The company has partnered with notable entities like University College London, Kings College London and Brunel University London, intending to use them as strategic partners to increase job seekers signing up to and using its app. QFinds will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£222,866
